GLP-3 R (Retatrutide) is a synthetic peptide analog designed for advanced biochemical and pharmacological research. It functions as a triple receptor agonist targeting GLP-1, GIP, and Glucagon receptors, making it an exciting compound for the exploration of metabolic and energy-balance pathways in preclinical settings.
 
Normally, when we eat, natural hormones called GIP and GLP-1 are released by the gut. These hormones increase insulin release, suppress appetite, slow gastric emptying, and increase the feeling of fullness. GLP-3R works like our natural hormones GIP and GLP-1 by activating the GIP and GLP-1 receptors.
 
Triple agonists (what some refer to as "GLP-3 hybrids") have the following characteristics:
 
Mechanism: They are single-molecule peptides that activate three different receptors:
GLP-1 receptor: Reduces appetite and increases insulin secretion.
GIP receptor: Works with GLP-1 to enhance insulin release.
Glucagon receptor: Increases energy expenditure and fat breakdown.
 
This innovative peptide has been engineered to exhibit enhanced stability, prolonged half-life, and improved potency compared to native GLP-1. GLP-3R has shown promising results in preclinical studies, demonstrating significant weight loss, improved glucose homeostasis, and reduced inflammation. As a potential therapeutic agent, GLP-3R offers hope for individuals struggling with obesity and its associated comorbidities, providing a targeted approach to managing metabolic health. 
 
This product requires reconstitution.